Skip to content

Xenon Pharmaceuticals XENE Change in receivables

Change in receivables at other companies

Eli Lilly logo
Eli LillyLLY
$1.75B+225%
Medtronic logo
MedtronicMDT
$287M+15.3%
Alkermes logo
AlkermesALKS
$23.22M+135%

Other financials

Income statement

See full
Revenue--100%
Operating income-$112.3M-54.4%
Net income-$102.3M-57.3%
EPS (diluted)-$1.17-41.0%

Balance sheet

See full
Cash & equivalents$545.9M+368%
Total debt$7.5M-13.6%
Total equity$1.3B+90.0%
Total assets$1.4B+86.6%

Cash flow

See full
Operating cash flow-$88.9M-44.2%
CapEx$133.0K+209%
Free cash flow-$89.0M-44.3%

Valuation

See full
Market cap$5.11B+116%

Profitability

See full
Operating margin-4,974.3%
Net margin-4,612.1%
FCF margin-3,732.2%

Returns & leverage

See full
Return on equity-37.5%+8.7pp
Debt / equity0.0×
Current ratio27.8×+10.1×

Where this comes from

Reported directly by Xenon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xenon Pharmaceuticals's change in receivables?
Xenon Pharmaceuticals (XENE) reported change in receivables of -$205K in Q1 2026.
How has Xenon Pharmaceuticals's change in receivables changed year-over-year?
Xenon Pharmaceuticals's change in receivables decreased by 102.9% year-over-year, from $7.18M to -$205K.
What does change in receivables mean?
Change in total receivables including trade and non-trade receivables.